Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arch Biopartners Inc Ord (ACHFF)

Arch Biopartners Inc Ord (ACHFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 38,486
  • Shares Outstanding, K 66,933
  • Annual Sales, $ 200 K
  • Annual Income, $ -1,110 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta 1.53
  • Price/Sales 201.04
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 08/29/25
  • Next Earnings Date 03/02/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5178 +12.01%
on 02/09/26
0.7415 -21.78%
on 02/12/26
-0.0700 (-10.77%)
since 02/04/26
3-Month
0.5178 +12.01%
on 02/09/26
1.0165 -42.94%
on 01/12/26
-0.3498 (-37.62%)
since 12/04/25
52-Week
0.5178 +12.01%
on 02/09/26
1.4150 -59.01%
on 06/26/25
-0.6700 (-53.60%)
since 03/04/25

Most Recent Stories

More News
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman...

ARCH.VN : 0.790 (-2.47%)
ACHFF : 0.5800 (+0.87%)
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated...

ARCH.VN : 0.790 (-2.47%)
ACHFF : 0.5800 (+0.87%)
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites...

ARCH.VN : 0.790 (-2.47%)
ACHFF : 0.5800 (+0.87%)
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled...

ARCH.VN : 0.790 (-2.47%)
ACHFF : 0.5800 (+0.87%)
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

ARCH.VN : 0.790 (-2.47%)
ACHFF : 0.5800 (+0.87%)
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage...

ARCH.VN : 0.790 (-2.47%)
ACHFF : 0.5800 (+0.87%)

Business Summary

Arch Biopartners Inc. is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation. Arch Biopartners Inc. is based in TORONTO.

See More

Key Turning Points

3rd Resistance Point 0.5800
2nd Resistance Point 0.5800
1st Resistance Point 0.5800
Last Price 0.5800
1st Support Level 0.5800
2nd Support Level 0.5800
3rd Support Level 0.5800

See More

52-Week High 1.4150
Fibonacci 61.8% 1.0723
Fibonacci 50% 0.9664
Fibonacci 38.2% 0.8605
Last Price 0.5800
52-Week Low 0.5178

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar